Comparative Protective Effects of Anakinra and Tocilizumab in Experimental Ocular Ischemic Syndrome
International Journal of Molecular Sciences · 05.08.2026 · 27 (15) · 7029
DOI: 10.3390/ijms27157029 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 05.08.2026. Verfasst von Shavkatbek Karimov und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Mengücek Gazi Training and Research Hospital, Erzincan 24100, Turkey. Hauptthemen laut MEDLINE: Interleukin 1 Receptor Antagonist Protein, Antibodies, Monoclonal, Humanized, Ischemia, Reperfusion Injury. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Ocular ischemic syndrome (OIS) is a vision-threatening disorder characterized by retinal ischemia, oxidative stress, and inflammation. In this study, the protective effects of anakinra, an interleukin-1 receptor antagonist, were investigated and compared with those of tocilizumab, an interleukin-6 receptor antagonist. Twenty-four male Wistar rats were randomly assigned to four groups (n = 6 per group): sham-operated (SG), carotid artery clamping/unclamping (CUG), anakinra-treated carotid artery clamping/unclamping (ACUG), and tocilizumab-treated carotid artery clamping/unclamping (TCUG). An experimental ocular ischemic injury model induced by transient bilateral common carotid artery occlusion was established by transient bilateral common carotid artery clamping followed by reperfusion. Retinal tissues were analyzed for malondialdehyde (MDA), total glutathione (tGSH), superoxide dismutase (SOD), catalase (CAT), tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and interleukin-6 (IL-6) levels, and histopathological examinations were performed. OIS markedly increased MDA, TNF-α, IL-1β, and IL-6 levels while significantly decreasing tGSH, SOD, and CAT activities. Both anakinra and tocilizumab attenuated oxidative stress and inflammatory responses; however, anakinra produced notably greater improvements in MDA, tGSH, SOD, and CAT levels. Histopathological evaluation demonstrated that both treatments reduced retinal injury, edema, vascular congestion, and inflammatory cell infiltration. Although retinal architecture appeared slightly better preserved in the anakinra-treated group, histopathological scores were comparable between the treatment groups. These findings suggest that anakinra may attenuate oxidative and inflammatory retinal damage in this experimental ocular ischemic injury model and may provide greater biochemical protection than tocilizumab, whereas histopathological protection was comparable between treatments. Nevertheless, further experimental and clinical studies are required to confirm these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Mengücek Gazi Training and Research Hospital, Erzincan 24100, Turkey.
- Anesthesia Program, Vocational School of Health Services, Erzincan Binali Yıldırım University, Erzincan 24100, Turkey.
- Department of Pharmacology, Faculty of Medicine, Erzincan Binali Yıldırım University, Erzincan 24100, Turkey.
- Department of Pharmacology, Azerbaijan Medical University, Baku AZ1000, Azerbaijan.
- Department of Histology and Embryology, Faculty of Medicine, Erzincan Binali Yıldırım University, Erzincan 24100, Turkey.
- Department of Medical Biochemistry, Faculty of Medicine, Erzincan Binali Yıldırım University, Erzincan 24100, Turkey.
ORCID-Profile: Esra Tuba Sezgin, Bahadir Suleyman, Taha Abdulkadir Coban, Halis Suleyman, Kemal Bayrakceken
Zitieren
APA
Karimov, S., Sezgin, E. T., Mammadov, R., Suleyman, B., Yaqudov, K., Yazici, G. N., Coban, T. A., Suleyman, H., & Bayrakceken, K. (2026). Comparative Protective Effects of Anakinra and Tocilizumab in Experimental Ocular Ischemic Syndrome. International Journal of Molecular Sciences, 27(15), 7029. https://doi.org/10.3390/ijms27157029
Vancouver
Karimov S, Sezgin ET, Mammadov R, Suleyman B, Yaqudov K, Yazici GN, et al. Comparative Protective Effects of Anakinra and Tocilizumab in Experimental Ocular Ischemic Syndrome. International Journal of Molecular Sciences. 2026;27(15):7029. doi:10.3390/ijms27157029
BibTeX
@article{Karimov2026,
author = {Karimov, Shavkatbek and Sezgin, Esra Tuba and Mammadov, Renad and Suleyman, Bahadir and Yaqudov, Kamandar and Yazici, Gulce Naz and Coban, Taha Abdulkadir and Suleyman, Halis and Bayrakceken, Kemal},
title = {Comparative Protective Effects of Anakinra and Tocilizumab in Experimental Ocular Ischemic Syndrome},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {15},
pages = {7029},
doi = {10.3390/ijms27157029}
}
EUVIMED